Phone: 203-208-1918
Fax: 203-433-4068
Website: http://axiomxinc.com

Contact(s)
[email protected]

General Information
AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.

Using its proprietary phage display libraries and “rapid liquid” approach to screening and affinity maturation, AxioMx has shortened typical monoclonal antibody development times from 4 to 6 months to as little as 8 weeks. The proprietary AxioMx platforms enable fast delivery of highly specific, high affinity, and reproducible recombinant antibodies that are optimized to work in a desired application. AxioMx antibodies are generated entirely in vitro which enables consistent antibody quality across production batches.

AxioMx services are used in research and diagnostic applications across pharma, biotech, diagnostic, academic and life science organizations. Research groups that need a custom antibody fast as well as an antibody that is optimized for their specific assay will benefit from these services.

Research Activities
AxioMx invests in research activities that will expand its recombinant antibody portfolio and the speed at which it can develop antibodies.

Other Information
Ownership: Private
CT Employees: 12
World Employees: 12

Back